Actively Recruiting
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
Led by Mayo Clinic · Updated on 2026-05-07
116
Participants Needed
3
Research Sites
122 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximately 15-18 months despite therapy. Studies have shown that having a higher-than-normal amount of glucose in the blood (hyperglycemia) during radiation therapy is associated with poorer survival outcomes in glioblastoma patients. Hyperglycemia in glioblastoma patients is often driven by steroids that are commonly used during treatment. CGM uses a device that places a sensor under the skin that monitors glucose levels at regular intervals, providing real-time, or near real-time, glucose information. This can help to identify when a patient has changes in their glucose levels so they may receive necessary interventions or medications sooner. CGM may be an effective way for glioblastoma patients to manage their glucose levels, which may improve survival.
CONDITIONS
Official Title
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Presumed newly diagnosed glioblastoma based on brain MRI findings
- Age 18 years or older at consent
- Karnofsky performance status of 70 or higher
- Absolute neutrophil count of at least 1.5 x 10^9/L
- Platelet count of at least 100 x 10^9/L
- Hemoglobin level of at least 9 g/dL
- Serum creatinine less than or equal to 1.5 times upper limit of normal or creatinine clearance at least 60 mL/min
- Aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5 times upper limit of normal
- Total bilirubin less than or equal to 1.5 times upper limit of normal
- Willing and able to use a continuous glucose monitoring device and attend dietary counseling sessions
You will not qualify if you...
- Recurrent glioblastoma or prior therapy beyond surgery or biopsy
- History of eating disorders or substance use disorder within the past 12 months
- Any uncontrolled or inadequately managed medical illness that could interfere with participation
- Diagnosis of another active cancer requiring treatment
- Pregnancy or breastfeeding at enrollment
- Documented history of type 1 diabetes mellitus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Mayo Clinic in Arizona
Phoenix, Arizona, United States, 85054
Not Yet Recruiting
2
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224
Not Yet Recruiting
3
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here